Celularity Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Andrew L Pecora. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Andrew L Pecora has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CELU / Celularity Inc. President 2,469,282
US:CLBS / Caladrius Biosciences Inc Director 12,500
US:TLOG / TetraLogic Pharmaceuticals Corporation Director 184,830
US:US92942V2088 / VYANT BIO INC Director 2,391
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Andrew L Pecora. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CELU / Celularity Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CELU / Celularity Inc. Insider Trades
Insider Sales CELU / Celularity Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CELU / Celularity Inc. Insider Trades
Insider Purchases LSTA / Lisata Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2014-11-24 NBS Pecora Andrew L 12,500 4.0120 12,500 4.0120 50,150 731

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Sales LSTA / Lisata Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Purchases TLOG / TetraLogic Pharmaceuticals Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CELU / Celularity Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2015-07-10 TLOG Pecora Andrew L 10,000 2.4400 10,000 2.4400 24,400 5 2.85 4,100 16.80
2015-07-10 TLOG Pecora Andrew L 1,300 2.5400 1,300 2.5400 3,302
2015-07-10 TLOG Pecora Andrew L 92 2.5700 92 2.5700 236
2015-07-10 TLOG Pecora Andrew L 1,092 2.6500 1,092 2.6500 2,894
2015-07-10 TLOG Pecora Andrew L 908 2.6590 908 2.6590 2,414
2015-07-10 TLOG Pecora Andrew L 2,100 2.6900 2,100 2.6900 5,649
2015-07-10 TLOG Pecora Andrew L 10,000 2.7370 10,000 2.7370 27,370
2015-07-10 TLOG Pecora Andrew L 6,900 2.7430 6,900 2.7430 18,927
2015-07-10 TLOG Pecora Andrew L 7,608 2.7450 7,608 2.7450 20,884
2015-07-10 TLOG Pecora Andrew L 800 2.7500 800 2.7500 2,200
2015-07-10 TLOG Pecora Andrew L 9,200 2.7900 9,200 2.7900 25,668
2015-07-09 TLOG Pecora Andrew L 40,000 2.4000 40,000 2.4000 96,000
2015-07-09 TLOG Pecora Andrew L 10,000 2.4090 10,000 2.4090 24,090
2014-11-17 TLOG Pecora Andrew L 20,000 4.5320 20,000 4.5320 90,640
2013-12-17 TLOG Pecora Andrew L 26,551 7.0000 26,551 7.0000 185,857

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TLOG / TetraLogic Pharmaceuticals Corporation Insider Trades
Insider Sales TLOG / TetraLogic Pharmaceuticals Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CELU / Celularity Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TLOG / TetraLogic Pharmaceuticals Corporation Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Andrew L Pecora as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2021-09-17 2021-09-15 4 CELU Celularity Inc
Stock Option (Right to Buy)
A - Award 2,469,282 2,469,282
2016-06-23 2016-06-22 4 CLBS Caladrius Biosciences, Inc.
Options to Purchase Common Stock
A - Award 12,500 12,500
2016-06-23 2016-06-22 4 CLBS Caladrius Biosciences, Inc.
Common Stock
A - Award 7,500 393,784 1.94
2016-01-27 2016-01-25 4 CLBS Caladrius Biosciences, Inc.
Options to Purchase Common Stock
A - Award 15,000 15,000
2016-01-27 2016-01-25 4 CLBS Caladrius Biosciences, Inc.
Common Stock
A - Award 9,000 386,284 2.39
2015-08-27 2015-08-27 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 3,108 377,284 0.83 1.27 3,947 479,151
2015-08-14 2015-08-13 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 2,831 374,176 0.76 1.40 3,963 523,846
2015-07-30 2015-07-30 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 2,277 371,345 0.62 1.74 3,962 646,140
2015-07-17 2015-07-16 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 2,086 369,068 0.57 1.90 3,963 701,229
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 9,200 184,830 5.24 2.79 25,668 515,676
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 800 175,630 0.46 2.75 2,200 482,982
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 7,608 174,830 4.55 2.74 20,884 479,908
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 6,900 167,222 4.30 2.74 18,927 458,690
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 10,000 160,322 6.65 2.74 27,370 438,801
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 2,100 150,322 1.42 2.69 5,649 404,366
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 908 148,222 0.62 2.66 2,414 394,122
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 1,092 147,314 0.75 2.65 2,894 390,382
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 92 146,222 0.06 2.57 236 375,791
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 1,300 146,130 0.90 2.54 3,302 371,170
2015-07-14 2015-07-10 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 10,000 144,830 7.42 2.44 24,400 353,385
2015-07-13 2015-07-09 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 10,000 134,830 8.01 2.41 24,090 324,805
2015-07-13 2015-07-09 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 40,000 124,830 47.15 2.40 96,000 299,592
2015-07-02 2015-07-02 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 2,097 366,982 0.57 1.89 3,963 693,596
2015-07-02 2015-06-30 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 227 364,885 0.06 1.87 424 682,335
2015-07-02 2015-06-30 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 6,702 364,658 1.87 1.59 10,653 579,624
2015-06-18 2015-06-18 4 CLBS Caladrius Biosciences, Inc.
Common Stock, $0.001 par value
A - Award 1,597 357,956 0.45 1.95 3,114 698,014
2015-06-04 2015-06-04 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 1,330 356,359 0.37 2.34 3,112 833,880
2015-06-04 2015-06-02 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 10,000 355,029 2.90
2015-05-21 2015-05-21 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 1,354 345,029 0.39 2.30 3,114 793,567
2015-05-21 2015-05-19 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 925 343,675 0.27
2015-05-07 2015-05-07 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 1,308 342,750 0.38 2.38 3,113 815,745
2015-05-07 2015-04-29 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
F - Taxes -3,917 341,442 -1.13 2.87 -11,242 979,939
2015-04-23 2015-04-23 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 1,081 345,359 0.31 2.88 3,113 994,634
2015-04-13 2015-04-09 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 899 344,278 0.26 3.10 2,787 1,067,262
2015-03-27 2015-03-26 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 848 343,379 0.25 3.08 2,612 1,057,607
2015-03-12 2015-03-12 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 688 342,531 0.20 3.80 2,614 1,301,618
2015-02-26 2015-02-26 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 7 341,843 0.00 3.89 26 1,329,769
2015-02-12 2015-02-12 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 1,715 341,171 0.51 3.77 6,466 1,286,215
2015-02-12 2015-02-12 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 753 339,456 0.22 3.47 2,613 1,177,912
2015-01-30 2015-01-28 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Stock Option
A - Award 10,000 77,644 14.78 5.25 52,500 407,631
2015-01-29 2015-01-29 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 746 347,508 0.22 3.50 2,611 1,216,278
2015-01-15 2015-01-15 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 684 348,780 0.20 3.82 2,613 1,332,340
2015-01-02 2015-01-02 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 75,000 75,000
2015-01-02 2014-12-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 2,018 348,096 0.58 3.20 6,467 1,115,474
2015-01-02 2014-12-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 934 346,078 0.27 3.75 3,502 1,297,792
2014-12-18 2014-12-18 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 1,033 345,144 0.30 3.39 3,502 1,170,038
2014-12-04 2014-12-04 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 891 344,111 0.26 3.93 3,502 1,352,356
2014-11-25 2014-11-24 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
P - Purchase 12,500 343,220 3.78 4.01 50,150 1,376,999
2014-11-20 2014-11-20 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 809 330,720 0.25 4.33 3,503 1,432,018
2014-11-19 2014-11-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 20,000 84,830 30.85 4.53 90,640 384,450
2014-11-06 2014-11-06 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 699 329,911 0.21 5.01 3,502 1,652,854
2014-10-23 2014-10-23 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 670 329,212 0.20 5.23 3,504 1,721,779
2014-10-09 2014-10-09 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 665 328,542 0.20 5.27 3,505 1,731,416
2014-09-25 2014-09-25 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 657 327,877 0.20 5.33 3,502 1,747,584
2014-09-11 2014-09-11 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 633 327,220 0.19 5.53 3,500 1,809,527
2014-08-28 2014-08-28 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 604 326,587 0.19 5.80 3,503 1,894,205
2014-08-14 2014-08-14 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 588 325,983 0.18 5.96 3,504 1,942,859
2014-08-01 2014-08-01 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 50,000 325,395 18.16
2014-08-01 2014-07-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 564 275,395 0.21 6.22 3,508 1,712,957
2014-07-17 2014-07-17 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 606 274,831 0.22 5.90 3,575 1,621,503
2014-07-03 2014-07-03 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 553 274,225 0.20 6.47 3,578 1,774,236
2014-07-01 2014-06-30 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 3,247 273,672 1.20 5.54 17,995 1,516,690
2014-06-19 2014-06-19 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 378 270,425 0.14 7.01 2,650 1,895,679
2014-06-05 2014-06-05 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 386 270,047 0.14 6.87 2,652 1,855,223
2014-05-22 2014-05-22 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 446 269,661 0.17 5.94 2,649 1,601,786
2014-05-09 2014-05-08 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 470 269,215 0.17 5.64 2,651 1,518,373
2014-04-25 2014-04-24 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 384 268,745 0.14 6.90 2,650 1,854,340
2014-04-11 2014-04-10 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 447 268,361 0.17 6.96 3,111 1,867,793
2014-03-28 2014-03-27 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 310 267,914 0.12 6.93 2,148 1,856,644
2014-03-13 2014-03-13 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 275 267,604 0.10 7.81 2,148 2,089,987
2014-02-27 2014-02-27 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 296 267,329 0.11 7.26 2,149 1,940,809
2014-02-14 2014-02-13 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 307 267,033 0.12 7.00 2,149 1,869,231
2014-02-14 2014-01-30 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 306 266,726 0.11 7.03 2,151 1,875,084
2014-02-14 2014-01-02 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
F - Taxes -4,402 266,420 -1.63 7.77 -34,204 2,070,083
2014-01-17 2014-01-16 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 315 270,822 0.12 6.83 2,151 1,849,714
2014-01-03 2014-01-02 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 100,000 100,000
2014-01-03 2014-01-02 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 46,976 270,507 21.02
2014-01-03 2014-01-02 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 315 223,531 0.14 7.77 2,448 1,736,836
2014-01-03 2013-12-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 3,608 223,216 1.64 4.84 17,481 1,081,482
2013-12-19 2013-12-19 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 423 219,608 0.19 6.10 2,580 1,339,609
2013-12-19 2013-12-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Series C Warrants
X - Other -161 0 -100.00
2013-12-19 2013-12-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Convertible Notes
C - Conversion -5,887 0 -100.00
2013-12-19 2013-12-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Series C Convertible Preferred Stock
C - Conversion -16,055 0 -100.00
2013-12-19 2013-12-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
X - Other 161 64,830 0.25 6.40 1,031 415,055
2013-12-19 2013-12-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
C - Conversion 5,887 64,669 10.01 7.00 41,209 452,683
2013-12-19 2013-12-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
C - Conversion 16,055 58,782 37.58
2013-12-19 2013-12-17 4 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
P - Purchase 26,551 42,727 164.14 7.00 185,857 299,089
2013-12-11 3 TLOG TETRALOGIC PHARMACEUTICALS CORP
Common Stock
16,176
2013-12-05 2013-12-05 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 411 219,185 0.19 6.27 2,577 1,374,290
2013-11-22 2013-11-21 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 434 218,774 0.20 6.06 2,630 1,325,770
2013-11-20 2013-11-18 4 CGIX CANCER GENETICS, INC
Common Stock, par value $0.0001 per share
S - Sale -1,700 2,391 -41.55 15.51 -26,375 37,096
2013-11-20 2013-11-18 4 CGIX CANCER GENETICS, INC
Common Stock, par value $0.0001 per share
S - Sale -29,161 4,091 -87.70 14.10 -411,217 57,690
2013-11-20 2013-11-18 4 CGIX CANCER GENETICS, INC
Common Stock, par value $0.0001 per share
S - Sale -18,839 33,252 -36.17 14.40 -271,225 478,729
2013-11-20 2013-11-18 4 CGIX CANCER GENETICS, INC
Common Stock, par value $0.0001 per share
S - Sale -300 52,091 -0.57 15.11 -4,532 786,923
2013-11-07 2013-11-06 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 406 218,340 0.19 6.53 2,651 1,425,760
2013-10-28 2013-10-24 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 383 217,934 0.18 6.93 2,654 1,510,283
2013-10-15 2013-10-10 4 CGIX CANCER GENETICS, INC
Stock Option (right to buy)
A - Award 10,000 10,000
2013-10-10 2013-10-10 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 391 217,551 0.18 6.78 2,651 1,474,996
2013-09-26 2013-09-26 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 297 217,160 0.14 8.94 2,655 1,941,410
2013-09-12 2013-09-12 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 307 216,863 0.14 8.64 2,652 1,873,696
2013-08-29 2013-08-29 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 365 216,556 0.17 7.26 2,650 1,572,197
2013-08-15 2013-08-15 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 355 216,191 0.16 7.46 2,648 1,612,785
2013-08-07 2013-08-05 4 NBS NeoStem, Inc.
Stock Option (right to purchase)
A - Award 27,500 27,500
2013-08-01 2013-08-01 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 401 215,836 0.19 7.05 2,827 1,521,644
2013-07-19 2013-07-18 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 464 215,434 0.22 6.00 2,784 1,292,604
2013-07-03 2013-07-03 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 4,150 2,149,700 0.19 0.56 2,324 1,203,832
2013-06-20 2013-06-20 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,671 2,145,550 0.31 0.53 3,536 1,137,142
2013-06-06 2013-06-06 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,547 2,138,879 0.31 0.54 3,535 1,154,995
2013-05-23 2013-05-23 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,096 2,132,332 0.29 0.58 3,536 1,236,753
2013-05-09 2013-05-09 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,547 2,126,236 0.31 0.54 3,535 1,148,167
2013-04-25 2013-04-25 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,612 2,119,689 0.27 0.63 3,536 1,335,404
2013-04-12 2013-04-10 4 CGIX CANCER GENETICS, INC
Convertible Note
C - Conversion 0
2013-04-12 2013-04-10 4 CGIX CANCER GENETICS, INC
Common Stock, par value $0.0001 per share
P - Purchase 50,000 52,391 2,091.18
2013-04-11 2013-04-11 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,199 2,114,077 0.25 0.68 3,535 1,437,572
2013-04-04 3 CGIX CANCER GENETICS, INC
Common Stock, par value $0.0001 per share
2,392
2013-03-28 2013-03-28 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,124 2,108,878 0.24 0.69 3,536 1,455,126
2013-03-14 2013-03-14 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,524 2,103,754 0.26 0.64 3,535 1,346,403
2013-03-01 2013-02-28 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,893 2,098,230 0.28 0.60 3,536 1,258,938
2013-02-20 2013-01-14 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,703 2,092,337 0.27 0.62 3,536 1,297,249
2013-02-01 2013-01-31 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,524 2,086,634 0.27 0.64 3,535 1,335,446
2013-01-18 2013-01-17 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,796 2,083,777 0.28 0.61 3,536 1,271,104
2013-01-04 2013-01-03 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 5,703 2,077,981 0.28 0.61 3,479 1,267,568
2013-01-04 2013-01-02 4 NBS NeoStem, Inc.
Stock Option (Right to Buy)
A - Award 300,000 300,000
2012-12-20 2012-12-20 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 7,226 2,072,278 0.35 0.61 4,408 1,264,090
2012-12-14 2012-12-06 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,887 2,065,052 0.33 0.64 4,408 1,321,633
2012-11-26 2012-11-26 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 4,786 2,058,175 0.23 0.71 3,390 1,458,011
2012-11-26 2012-11-26 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,934 2,053,389 0.34 0.67 4,646 1,375,771
2012-11-13 2012-11-08 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,362 2,046,445 0.31 0.63 4,008 1,289,260
2012-10-26 2012-10-25 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 6,771 2,040,083 0.33 0.71 4,807 1,448,459
2012-10-01 2012-09-27 4 NBS NeoStem, Inc.
Common Stock, $0.001 par value
A - Award 11,794 2,033,312 0.58 0.69 8,138 1,402,985
2012-04-30 2012-04-26 4 NBS NeoStem, Inc.
Stock Option (Right to Buy)
A - Award 140,000 140,000
2012-04-30 2012-04-26 4 NBS NeoStem, Inc.
Common stock, $0.001 par value
A - Award 7,536 2,021,518 0.37 0.36 2,713 727,746
2012-04-16 2012-04-12 4 NBS NeoStem, Inc.
Common stock, $0.001 par value
A - Award 8,478 2,013,982 0.42 0.32 2,713 644,474
2012-01-06 2012-01-04 4 NBS NeoStem, Inc.
Stock Options (Right to Buy)
A - Award 175,000 175,000
2011-01-21 3 NBS NeoStem, Inc.
Common Stock, par value $0.001 per share
1,844,527
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)